The TRANSFORM-HF trial found no significant difference in all-cause mortality and all-cause hospitalization following hospitalization for heart failure (HF) with a diuretic strategy of torsemide versus furosemide. However, the impact of diuretic dosing on the trial results and whether the relationship...
Also Liked This Issue Views 116,327 Citations 106 0 Download PDF More Cite This Permissions Original Investigation January 17, 2023 Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart FailureThe TRANSFORM-HF Randomized Clinical Trial Robert J....
R AHA 2022: Torsemide Comparison With Furosemide for Management of Heart Failure - TRANSFORM-HF Trial By AHA 2022 Conference Coverage FEATURING Robert Mentz November 21, 2022 Comments 3 Login to view comments. Click here to Login
This post hoc analysis of the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) randomized clinical trial investigates
where rjk(t) is the contribution to the jth IMF from the added white noise of the kth trial of the jth IMF in the noise-added signal. The amplitude of noise wi(t) is not necessarily small. But, the ensemble number of the trials, N, has to be large. The difference between the tru...
However, the impact of baseline renal function on these findings is unknown.Methods: The TRANSFORM-HF trial randomized patients hospitalized for HF to a long-term strategy of torsemide versus furosemide, and enrolled patients across the spectrum of renal function excluding patients on dialysis. In ...
This improved diagnostic ability was based on outcomes from the MIDHeFT (Medtronic Impedance Diagnostics in Heart Failure Trial) [5] and FAST (fast accumulations status trial) [6] trials in humans. Sensitivity improvements were realized by measuring the impedance between the left ventricular (LV) ...
In [19], frequency domain parameters, namely Very Low Frequency (VLF), Low Frequency (LF), High Frequency (HF), total power and the ratio of LF to HF powers, are computed from the HRV signals. The VLF power is found to be an independent risk predictor in CHF patients. Depressed HRV ...